Dare Bioscience, Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 78/100
What the filing says
Dare Bioscience has received a multiyear grant from the Gates Foundation (now rebranded) for development of DARE LARC1, a long-acting hormonal contraceptive implant for low-resource settings. Total committed grant: $48,945,928 across payments from July 2021 through project end November 1, 2026 (extended via Amendment 6 to December 31, 2027). Amendment 7 (June 2026) confirms $37.35M paid to date; remaining tranches scheduled through end of 2027. Grant includes global access commitments, IP reporting requirements, and humanitarian license to Foundation.
Why this rating
Grant is ~2.3× company's $21.3M market cap. Provides critical R&D funding for lead program and extends runway, but subject to milestones and Foundation control over IP/global access.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.